- Home
- AUUD vs SNPX Comparison
AUUD vs SNPX Comparison
Compare AUUD & SNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- SNPX
- Stock Information
- Founded
- AUUD 2012
- SNPX 2012
- Country
- AUUD United States
- SNPX United States
- Employees
- AUUD N/A
- SNPX N/A
- Industry
- AUUD Computer Software: Prepackaged Software
- SNPX Medicinal Chemicals and Botanical Products
- Sector
- AUUD Technology
- SNPX Health Care
- Exchange
- AUUD Nasdaq
- SNPX Nasdaq
- Market Cap
- AUUD 3.1M
- SNPX 3.7M
- IPO Year
- AUUD 2021
- SNPX N/A
- Fundamental
- Price
- AUUD $0.49
- SNPX $3.30
- Analyst Decision
- AUUD
- SNPX Strong Buy
- Analyst Count
- AUUD 0
- SNPX 1
- Target Price
- AUUD N/A
- SNPX $14.00
- AVG Volume (30 Days)
- AUUD 1.2M
- SNPX 33.7K
- Earning Date
- AUUD 11-07-2024
- SNPX 11-12-2024
- Dividend Yield
- AUUD N/A
- SNPX N/A
- EPS Growth
- AUUD N/A
- SNPX N/A
- EPS
- AUUD N/A
- SNPX N/A
- Revenue
- AUUD N/A
- SNPX N/A
- Revenue This Year
- AUUD N/A
- SNPX N/A
- Revenue Next Year
- AUUD N/A
- SNPX N/A
- P/E Ratio
- AUUD N/A
- SNPX N/A
- Revenue Growth
- AUUD N/A
- SNPX N/A
- 52 Week Low
- AUUD $0.43
- SNPX $2.32
- 52 Week High
- AUUD $11.75
- SNPX $7.23
- Technical
- Relative Strength Index (RSI)
- AUUD 43.62
- SNPX 51.02
- Support Level
- AUUD $0.46
- SNPX $3.10
- Resistance Level
- AUUD $0.61
- SNPX $3.58
- Average True Range (ATR)
- AUUD 0.05
- SNPX 0.33
- MACD
- AUUD -0.00
- SNPX -0.03
- Stochastic Oscillator
- AUUD 19.74
- SNPX 32.04
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products include Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About SNPX Synaptogenix Inc.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.